Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors Read Press release Chronic Pain: A Global Burden According to the National Institutes of Health, over 40 million adults in the United States and over 1 billion people worldwide suffer from chron...
Centrexion Therapeutics 美国膝关节药物研发商 认领企业 委托联系 D轮 运营中 美国 | 查看官网 Centrexion Therapeutics是一家美国膝关节药物研发商,主要面向中度至重度膝盖骨关节炎慢性疾病的用户,通过搭建非阿片类和非类固醇类疼痛治疗产品生产线,为用户提供新型非阿片类药物,主要产品为CNTX-4975。
Centrexion Therapeutics is transforming the treatment of chronic pain by advancing one of the largest, exclusively pain-focused clinical pipelines of novel, non-opioid therapies. It aims to bridge the safety and efficacy gaps in current approaches to chronic pain management.The pipeline represents the ...
产品介绍 Centrexion Therapeutics专注于治疗中度至重度膝盖骨关节炎慢性疼痛,同时针对这一...详细 品牌专辑推荐 推荐品牌 垂直电商易起行 OTA直连 综合消费者服务!Creatice"AIWAYS 爱驰汽车""AutocloudPro 车通云""BYTON 拜腾""Cambricon Technologies 寒武纪""Clobotics 上海扩博""ExPace 科工火箭""Momenta 初速度"...
Assignee: Centrexion Therapeutics Corporation (Boston, MA, US) International Classes: A61K31/403; A61K31/4155; A61K31/416; A61K31/423; A61K31/426; A61K31/429; A61K31/437; A61K31/4375; A61K31/4439; A61K31/4709; A61K31/4725; A61K31/497; A61K31/501; A61K31/502; A61K31/...